considered major global medical burdens with high prevalence and steeply rising incidence.
Despite the characterization of numerous pathophysiologic pathways leading to metabolic
disorder, lipid accumulation, inflammation, fibrosis, and ultimately end-stage liver disease or
liver cancer formation, so far no causal pharmacological therapy is available. Drug
development for NAFLD and NASH is limited by long disease duration and slow progression …